David R. Bauer
Lawyers

Filters
Biodesix $72 million IPO
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…
Abcam $180 million U.S. IPO of ADSs
Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…
Aligos Therapeutics $150 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos…
Royalty Pharma $728 million secondary offering
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…
Aziyo Biologics $50 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $50 million initial public offering of common stock by Aziyo Biologics, Inc. The common stock…
Beam Therapeutics $127 million offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…
Gilead Sciences $7.25 billion senior notes offering
Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…
Medtronic Global Holdings €6.25 billion notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €6.25 billion aggregate principal amount of notes by Medtronic Global…
ADC Therapeutics $204 million SEC-registered offering
Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…
Humanigen stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,200,000 shares of common stock of…